Article Text

Download PDFPDF
Non-proliferative type II macular telangiectasia variant with subfoveal detachment: role of anti-VEGF therapy
  1. George J Manayath1,
  2. Ratnesh Ranjan1,
  3. C K Nagesha2,
  4. Venkatapathy Narendran1
  1. 1Vitreo-Retina Services, Aravind Eye Hospital, Coimbatore, Tamil Nadu, India
  2. 2Vitreo-Retina Services, Aravind Eye Hospital, Pudducherry, Tamil Nadu, India
  1. Correspondence to Dr Ratnesh Ranjan, Vitreo-Retina Services, Aravind Eye Hospital Coimbatore, Coimbatore, TN 641014, India; drratnesh16{at}


Aims To describe a rare variant of non-proliferative stage of type II macular telangiectasia (MacTel2) with the presence of subfoveal detachment (SFD) and its response to intravitreal antivascular endothelial growth factor (VEGF) therapy.

Methods A retrospective case series of patients diagnosed with a rare variant of non-proliferative MacTel2 (defined as MacTel2 with the presence of SFD on optical coherence tomography (OCT) in the absence of subretinal neovascularisation, confirmed on fluorescein angiography (FA)) over a period of 2 years. Patients were studied with biomicroscopy, OCT and FA. Patients were managed either with observation or anti-VEGF therapy.

Results Twenty eyes of 13 patients, all female with a mean age of 52.2±6.1 years, were diagnosed with this variant of non-proliferative MacTel2. The best-corrected visual acuity at presentation ranged from 20/20 to 20/120. Six eyes were lost to follow-up. Eight eyes were kept under observation for a mean follow-up of 7.3±2.2 months and did not show resolution. Eight eyes underwent anti-VEGF therapy with a mean number of intravitreal injections of 2±1.07 per eye during a mean follow-up of 9.38±5.5 months. All eyes showed complete resolution of SFD, with a visual improvement of ≥1 line of Snellen’s acuity in 87.5% of the eyes.

Conclusion This is the largest series of a variant of non-proliferative MacTel2 with SFD, which shows good anatomical and functional response to anti-VEGF therapy, in comparison to observation alone. Careful evaluation of the OCT images may be helpful in predicting the visual prognosis with anti-VEGF therapy.

  • retina
  • treatment medical

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors GJM: conception of the study, data and imaging analysis and manuscript review. RR: data collection and statistical analysis, drafting of the manuscript and revision. CKN: data collection, drafting of the manuscript. VN: conception of the study and critical review.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No data are available.

  • Author note This study was conducted at the Retina department of Coimbatore and Pudducherry centre of Aravind Eye Hospital & Postgraduate Institute of Ophthalmology.